These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

187 related articles for article (PubMed ID: 35401563)

  • 21. Pneumonitis, appendicitis, and biliary obstruction during toripalimab treatment in a patient with extensive-stage small-cell lung cancer: a case report.
    Qu Y; Wang Z; Feng J; Wang L; Liu H; Liu D; Zhao Y; Yu R; Li W; Sun D; Yu H
    Ann Palliat Med; 2021 Aug; 10(8):9267-9275. PubMed ID: 34488412
    [TBL] [Abstract][Full Text] [Related]  

  • 22. "Hot Cross Bun" Sign in a Patient with Glutamic Acid Decarboxylase 65-KDa Isoform Associated Cerebellar Ataxia: Case Report and Review of the Literature.
    Duan RN; He JZ; Cao LL
    Cerebellum; 2024 Jun; 23(3):1204-1210. PubMed ID: 37948023
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Neoadjuvant PD-1 blockade with toripalimab, with or without celecoxib, in mismatch repair-deficient or microsatellite instability-high, locally advanced, colorectal cancer (PICC): a single-centre, parallel-group, non-comparative, randomised, phase 2 trial.
    Hu H; Kang L; Zhang J; Wu Z; Wang H; Huang M; Lan P; Wu X; Wang C; Cao W; Hu J; Huang Y; Huang L; Wang H; Shi L; Cai Y; Shen C; Ling J; Xie X; Cai Y; He X; Dou R; Zhou J; Ma T; Zhang X; Luo S; Deng W; Ling L; Liu H; Deng Y
    Lancet Gastroenterol Hepatol; 2022 Jan; 7(1):38-48. PubMed ID: 34688374
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Metastatic germ cell tumor showing a durable response to the anti-PD-1 antibody toripalimab.
    Wang R; Wang W; Zhang W; Bai Y
    Immunotherapy; 2023 Jun; 15(8):565-572. PubMed ID: 37020394
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Elevated Adenosine Deaminase Levels in the Cerebrospinal Fluid in Immune Checkpoint Inhibitor-induced Autoimmune Encephalitis.
    Fujiwara S; Mimura N; Yoshimura H; Fujimoto D; Ito M; Mori R; Ito J; Tomii K; Kawamoto M; Kohara N
    Intern Med; 2019 Oct; 58(19):2871-2874. PubMed ID: 31243206
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Plasmapheresis and IVIG for Treatment of Non-Tumor Anti-Tr/DNER Antibody-Associated Ataxia: A Case Report.
    Adibi A; Rastegar-Kashkouli A; Yousefi P; Adibi I; Ahmadi E; Naghavi S
    Cerebellum; 2024 Oct; 23(5):2208-2213. PubMed ID: 38874737
    [TBL] [Abstract][Full Text] [Related]  

  • 27. [A case of human immunodeficiency virus infection with cerebellar ataxia that suggested by an association with autoimmunity].
    Nagao S; Kondo T; Nakamura T; Nakagawa T; Matsumoto S
    Rinsho Shinkeigaku; 2016 Apr; 56(4):255-9. PubMed ID: 27010096
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Case Report: Autoimmune Encephalitis Associated With Anti-glutamic Acid Decarboxylase Antibodies: A Pediatric Case Series.
    Ren C; Ren H; Ren X; Zhang W; Li J; Dai L; Guan H; Fang F
    Front Neurol; 2021; 12():641024. PubMed ID: 33912125
    [No Abstract]   [Full Text] [Related]  

  • 29. An unusual case of immune-related gastritis in one patient receiving toripalimab therapy.
    Chen X; Shi W
    Immunotherapy; 2023 Apr; 15(5):335-342. PubMed ID: 36852424
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Successful treatment of metastatic vulvar malignant melanoma with toripalimab: A rare case report and review of the literature.
    Li YH; Zhou Y; Zhang GJ; Wang YW; Wang JG; Wang XH; Li YF
    Medicine (Baltimore); 2022 Sep; 101(36):e30239. PubMed ID: 36086787
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Cerebellar ataxia with anti-mGluR1 auto-antibody in a pediatric patient: A case report.
    Wang H; Yi B; Wang M; Wang Y; Wang S; Wang L; Song H; Fu J; Wang X; Cao L
    J Neuroimmunol; 2023 May; 378():578082. PubMed ID: 37119682
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Glycosylation-independent binding of monoclonal antibody toripalimab to FG loop of PD-1 for tumor immune checkpoint therapy.
    Liu H; Guo L; Zhang J; Zhou Y; Zhou J; Yao J; Wu H; Yao S; Chen B; Chai Y; Qi J; Gao GF; Tan S; Feng H; Yan J
    MAbs; 2019; 11(4):681-690. PubMed ID: 30892132
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Autoimmune Cerebellar Ataxia Associated with Anti-Glutamate Receptor δ2 Antibodies: a Rare but Treatable Entity.
    Khatib L; Do LD; Benaiteau M; Villagrán-García M; Scharf M; Meyer P; Haidar LA; Demeret S; Honnorat J
    Cerebellum; 2024 Feb; 23(1):260-266. PubMed ID: 36696031
    [TBL] [Abstract][Full Text] [Related]  

  • 34. GAD65 autoimmunity after treatment with nivolumab: a multifocal presentation.
    Maniscalco GT; Zekeridou A; Allegorico L; Ranieri A; Napolitano M; Pezzella M; Gatta LD; Manzo V; Ferrari S; Mariotto S
    Neurol Sci; 2021 Oct; 42(10):4289-4291. PubMed ID: 33977307
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Glutamate receptor antibodies in neurological diseases: anti-AMPA-GluR3 antibodies, anti-NMDA-NR1 antibodies, anti-NMDA-NR2A/B antibodies, anti-mGluR1 antibodies or anti-mGluR5 antibodies are present in subpopulations of patients with either: epilepsy, encephalitis, cerebellar ataxia, systemic lupus erythematosus (SLE) and neuropsychiatric SLE, Sjogren's syndrome, schizophrenia, mania or stroke. These autoimmune anti-glutamate receptor antibodies can bind neurons in few brain regions, activate glutamate receptors, decrease glutamate receptor's expression, impair glutamate-induced signaling and function, activate blood brain barrier endothelial cells, kill neurons, damage the brain, induce behavioral/psychiatric/cognitive abnormalities and ataxia in animal models, and can be removed or silenced in some patients by immunotherapy.
    Levite M
    J Neural Transm (Vienna); 2014 Aug; 121(8):1029-75. PubMed ID: 25081016
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [Autoimmune cerebellar ataxia].
    Nanri K; Okuma M; Sato S; Taguchi T; Tanaka N
    Nihon Rinsho; 2015 Sep; 73 Suppl 7():632-7. PubMed ID: 26480769
    [No Abstract]   [Full Text] [Related]  

  • 37. Immune-Related Adverse Events in PD-1 Treated Melanoma and Impact Upon Anti-Tumor Efficacy: A Real World Analysis.
    Bastacky ML; Wang H; Fortman D; Rahman Z; Mascara GP; Brenner T; Najjar YG; Luke JJ; Kirkwood JM; Zarour HM; Davar D
    Front Oncol; 2021; 11():749064. PubMed ID: 34900695
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Glial fibrillary acidic protein (GFAP) associated autoimmune meningoencephalitis in a patient receiving nivolumab.
    Kapadia RK; Ney DE; Hannan M; Farley M; Pastula DM; Piquet AL
    J Neuroimmunol; 2020 Jul; 344():577259. PubMed ID: 32416558
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Association of Immune-Mediated Cerebellitis With Immune Checkpoint Inhibitor Therapy.
    Zurko J; Mehta A
    Mayo Clin Proc Innov Qual Outcomes; 2018 Mar; 2(1):74-77. PubMed ID: 30225435
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Recurrent Cystitis Associated With 2 Programmed Death 1 Inhibitors: A Rare Case Report and Literature Review.
    Fan Y; Zhao J; Mi Y; Zhang Z; Geng Y; Zhou L; Shen L; Zhang Z
    J Immunother; 2023 Nov-Dec 01; 46(9):341-345. PubMed ID: 37721343
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.